{
    "nctId": "NCT02491697",
    "briefTitle": "Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer",
    "officialTitle": "Randomized Controlled Trial Comparing Dendritic Cells Co-cultured With Cytokine-induced Killer Cells Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "Overall Survival(OS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed with advanced breast cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 2.\n* Hemoglobin\u226510.0g/dL, Neutrophil count\u22651.5\u00d710\\^9/L, Platelet count\u226575\u00d710\\^9/L; total bilirubin(TBIL)\u22641.5\u00d7ULN; alkaline phosphatase(AKP), aspartate aminotransferase(AST),ALT\u22642.5\u00d7ULN(without metastasis of the liver), AKP,AST,ALT\u22645\u00d7ULN(with metastasis of the liver); BUN\u22641.5\u00d7ULN, Cr\u22641.5\u00d7ULN.\n* Patient received 1-2 kinds of cytotoxic chemotherapy previously.\n* Patient never received capecitabine or other oral fluorouracil.\n\nExclusion Criteria:\n\n* Patients who are suffering from serious organ dysfunction.\n* HIV positive or other immunodeficiency disease.\n* Patients who had used long time or are using immunosuppressant drugs.\n* Patients who had active infection.\n* Patients who were allergic to fluorouracil.\n* Pregnant or lactating women.\n* History of other malignancies.\n* Other situations that the researchers considered unsuitable for this study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}